International Stem Cell Corp. (OTCMKTS:ISCO – Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.15 and traded as high as $0.1850. International Stem Cell shares last traded at $0.17, with a volume of 501 shares.
International Stem Cell Stock Performance
The company has a market cap of $1.36 million, a price-to-earnings ratio of -2.83 and a beta of 0.06. The business has a fifty day moving average of $0.16 and a two-hundred day moving average of $0.15.
International Stem Cell (OTCMKTS:ISCO – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.03) earnings per share for the quarter. The company had revenue of $2.32 million during the quarter.
About International Stem Cell
International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.
In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.
Read More
- Five stocks we like better than International Stem Cell
- Workday Validates AI Flywheel: Stock Price Recovery Begins
- HubSpot at 2019 Levels Is an Opportunity—Not a Warning
- Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.
